HER2-Positive Breast Cancer: A Review of Data from the SABCS 2021 Virtual Meeting - Episode 4

SABCS 2021: Novel Approaches to Breast Cancer Management

, , ,

After discussing a few more key datasets from the SABCS 2021 Virtual Meeting, expert panelists discuss how they would approach treatment in several subsets of breast cancer.

Data from the following clinical trials are discussed:

  • GS3-03: Genomic analysis of 733 HER2+ breast cancer identifies recurrent pathway alterations associated with anti-HER2 resistance and new therapeutic vulnerabilities
  • GS1-05: Datopotamab deruxtecan (Dato-DXd) in advanced/metastatic HER2- breast cancer: results from the phase 1 TROPION-PanTumor01 study
  • GS04-09: Quality-of-life results from OlympiA: a phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after neoadjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2- early breast cancer